Guidance for Temperature-Controlled Medicinal Products: Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment
The PDA technical report on maintaining the quality of temperature-sensitive medicinal products through the transportation environment (Technical Report No. 39, Revised 2021). It provides an industry methodology for a quality management system covering distribution — from the shipping site where product is prepared for transport to its arrival at the receiving site — with a qualification model running from process design through implementation and operation to verification.
What this does not cover
stated in the document's own scope- Covers the transportation of temperature-sensitive medicinal products from shipping site to receiving site; warehouse GDP obligations and licensing sit in the regulatory GDP frameworks.
- An industry technical report: it supports compliance with GDP and GMP requirements but imposes no obligations of its own.
- Addresses transportation process design and qualification; the stability data defining a product's temperature limits come from the manufacturer's stability programme.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
PDA Technical Report No. 39, Guidance for Temperature-Controlled Medicinal Products, is the pharmaceutical industry's engineering methodology for keeping temperature-sensitive products within their limits through the transportation environment. The current edition, Revised 2021, describes a quality management system for distribution spanning the operation from the shipping site — where product is prepared for transport — to arrival at the receiving site, and a qualification model that runs from process design through implementation and operation to verification. Its premise is that distribution is a dynamic process, exposed to an external environment less controllable than a manufacturing process and handled by parties outside the manufacturer's direct management, so shipping solutions must be designed and qualified against product stability limits and real lane conditions rather than assumed.
Scope & applicability
All stakeholders shipping temperature-sensitive medicinal and pharmaceutical products: manufacturers, distributors, and logistics providers designing, qualifying, and operating temperature-controlled transportation. It is industry methodology supporting regulatory GDP requirements, not itself a regulation.
Legal basis & how it acquires force
A technical report of the Parenteral Drug Association (PDA), an industry association: it is consensus industry methodology, not law, and its text is a purchase-gated PDA publication. Its role is to supply the engineering "how" behind binding distribution requirements — the temperature-management expectations of the EU GDP guidelines, national GDP rules, and the storage and holding provisions of GMP regulations. First published in 2005, revised in 2007, and revised again in 2021.
Document structure
| Part | Covers |
|---|---|
| Scope and distribution environment | The shipping-site-to-receiving-site operation covered and the characteristics of the transportation environment |
| Quality management system for distribution | The quality-system elements a temperature-controlled distribution operation requires |
| Process design | Designing shipping solutions against product stability limits, packaging performance, and lane conditions |
| Qualification and verification | The model running from design through implementation and operation to verification of the shipping process |
| Operation and stakeholders | Running the qualified process across the parties in the pharmaceutical supply chain |
Key requirements
- A quality management system extending across the distribution and transportation operation
- Transportation processes designed against product stability limits and lane conditions
- Qualification of shipping systems from design through implementation and operation to verification
- Controls maintaining product temperature within defined limits from shipping site to receiving site
Implementation tips
- Use TR 39 as the engineering method behind the regulatory texts: EU GDP and USP <1079> say what must be achieved; TR 39 describes how industry designs and qualifies the shipping solution
Revision notes
First published 2005, revised 2007, and revised again in 2021 — the current edition. The full text is a purchase-gated PDA publication.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
TR 39 is the industry-methodology layer beneath the regulatory and compendial cold-chain texts: the EU GDP guidelines and WHO TRS 961 Annex 9 state what storage and transport must achieve, USP <1079> frames the risks for the US supply chain, and TR 39 describes how industry designs, qualifies, and operates the shipping solution. PDA technical reports carry no regulatory force but are widely used as the reference engineering practice in distribution qualification.
PDA TR No. 39: frequently asked questions
Quick answers to common questions about PDA TR No. 39.
What is PDA Technical Report No. 39?
The PDA's industry guidance for maintaining the quality of temperature-sensitive medicinal products through the transportation environment — a quality management system for distribution plus a qualification model from process design through implementation and operation to verification. The current edition is Revised 2021.
Is PDA TR 39 a regulatory requirement?
No. It is a technical report from an industry association and imposes no obligations. Its value is methodological: it describes how to design and qualify shipping solutions that meet the temperature-management requirements regulators state in GDP and GMP texts.
How does TR 39 relate to USP <1079> and WHO TRS 961 Annex 9?
They occupy different layers. USP <1079> and the WHO model guidance state the practice standard — the risks to manage and the controls expected. TR 39 is the engineering method beneath them: designing the shipping solution against stability limits and lane data, then qualifying and verifying it in operation.
Is the text of TR 39 freely available?
No. PDA technical reports are purchase-gated publications available through the PDA bookstore and licensed standards distributors; SPEQ cites the report's metadata and role, not its text.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.